title: Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome.
authors.forename: Piotr
authors.initials: P
authors.lastname: Mazur
authors.forename: Tomasz
authors.initials: T
authors.lastname: Darocha
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Filip
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Grudzień
authors.forename: Rafał
authors.initials: R
authors.lastname: Drwiła
authors.forename: Bogusław
authors.initials: B
authors.lastname: Kapelak
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D001018:Aortic Diseases / Q000150:complications* / Q000473:pathology / Q000601:surgery; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy; D000069604:Dabigatran / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D004630:Emergencies; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; C000594745:idarucizumab; D000069604:Dabigatran